tiprankstipranks
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
Company Announcements

Nektar Therapeutics Is Worried About This – Should You Be Worried Too?

Nektar Therapeutics (NKTR) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Don't Miss Our Christmas Offers:

Nektar Therapeutics faces a significant business risk after receiving a notice from Nasdaq regarding non-compliance with the Minimum Bid Price Rule. The company’s common stock failed to maintain the required $1.00 minimum closing bid price, prompting a potential delisting. Although Nektar Therapeutics has been granted an extension until May 20, 2024, to meet the criteria, which may involve a reverse stock split, there is no certainty of success. If compliance is not achieved and delisting occurs, it could detrimentally impact the stock’s marketability and the company’s capital-raising capabilities.

The average NKTR stock price target is $1.00, implying 9.90% upside potential.

To learn more about Nektar Therapeutics’ risk factors, click here.

Related Articles
TheFlyNektar initiated with a Buy at H.C. Wainwright
TheFlyNektar presents preclinical data on NKTR-422 at ACR conference
TipRanks Auto-Generated NewsdeskNektar Therapeutics Reports Stable Q3 Earnings for 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App